A naturally hypersensitive glucocorticoid receptor elicits a compensatory reduction of hypothalamus–pituitary–adrenal axis activity early in ontogeny

Eduard Muráni1, Siriluck Ponsuksili1, Alexandra Jaeger1, Andreas Görrès1, Armin Tuchscherer2 and Klaus Wimmers1

1Genome Biology, and 2Genetics and Biometry, Leibniz Institute for Farm Animal Biology (FBN), Wilhelm-Stahl-Allee 2, 18196 Dummerstorf, Germany

We comprehensively characterized the effects of a unique natural gain-of-function mutation in the glucocorticoid receptor (GR), GRAla610Val, in domestic pigs to expand current knowledge of the phenotypic consequences of GR hypersensitivity. Cortisol levels were consistently reduced in one-week-old piglets, at weaning and in peripubertal age, probably due to a reduced adrenal capacity to produce glucocorticoids (GC), which was indicated by an adrenocortical thinning in GRAla610Val carriers. Adrenocorticotrophic hormone (ACTH) levels were significantly reduced in one-week-old piglets only. Expression analyses in peripubertal age revealed significant downregulation of hypothalamic expression of CRH and AVP, the latter only in females, and upregulation of hepatic expression of SERPINA6, by GRAla610Val. Transcriptional repression of proinflammatory genes in peripheral blood mononuclear cells (PBMCs) from GRAla610Val carriers was more sensitive to dexamethasone treatment ex vivo. However, no significant effects on growth, body composition, blood chemistry or cell counts were observed under baseline conditions. These results suggest that GRAla610Val-induced GR hypersensitivity elicits a compensatory reduction in endogenous, bioactive glucocorticoid levels via readjustment of the hypothalamus–pituitary–adrenal (HPA) axis early in ontogeny to maintain an adequate response, but carriers are more sensitive to exogenous GC. Therefore, GRAla610Val pigs represent a valuable animal model to explore GR-mediated mechanisms of HPA axis regulation and responses to glucocorticoid-based drugs.

1. Introduction

The glucocorticoid receptor (GR) is a member of the nuclear receptor superfamily of ligand-activated transcription factors. GR is ubiquitously expressed, and it is the primary mediator of the effects of glucocorticoids (GC) on a variety of physiological functions, including energy metabolism and immune responses [1]. Activated GRs repress the expression of a large set of proinflammatory genes [2,3]. Therefore, GR ligands, such as dexamethasone (DEX), have broad application in the treatment of inflammatory diseases and autoimmune disorders, and the ligands are among the most widely prescribed drugs in human and veterinary medicine [1,4]. However, the therapeutic use of GC-based drugs is limited by possible adverse side effects (e.g. osteoporosis [5]) and highly variable individual responses [6]. GRs are key players in the feedback regulation of the hypothalamus–pituitary–adrenal (HPA) axis and the orchestration of the stress response [7]. Impaired GR signalling may lead to maladaptive stress responses, which is implicated in the pathogenesis of stress-related psychiatric disorders in humans, such as major depression [8]. Diverse factors may influence GR signalling, including genetic and epigenetic...
targeted mutagenesis has provided important insights into the physiological functions and molecular actions of GR, and this technique is an indispensable tool to study the consequences of GR dysregulation. Most functionally and/or phenotypically characterized artificial and natural mutations cause GR deficiency [10–12]. Notably, GR loss-of-function mutations are associated with different phenotypic consequences, depending on which tissue or GR domain, i.e. signalling pathway, is affected [10,13].

However, little research has been performed on GR hypersensitivity, and the molecular causes and phenotypic consequences of this condition are not well understood [14,15]. Gain-of-function mutations of GRs, particularly in the ligand binding domain (LBD), are very rare [11,15]. The only phenotypically characterized model of a gain-of-function GR mutation is a knock-in of the GRM610 substitution in mice [16].

We recently discovered a natural alanine to valine substitution in the LBD of the porcine GR (GRAla610Val induced by SNP c.1829C>T in the porcine NR3C1 [17]), which causes large inter-individual variations in adrenal weight and stress-induced cortisol stress levels in domestic pigs [17]. We used an in vitro transactivation assay and demonstrated that the GRAla610Val substitution increased GC responsiveness of the porcine GR. The more GC-sensitive Val variant was associated with markedly lower adrenal weight and cortisol levels in slaughter blood. The GRAla610Val substitution, which occurred at a position directly adjacent to the site mutated by Zhang et al. [16], is the only known natural gain-of-function mutation of the GR-LBD. In this study, we exploited this unique animal model to comprehensively characterize the phenotypic consequences of GR hypersensitivity in a natural setting. We investigated the effect of the GRAla610Val substitution on different aspects of HPA axis function during ontogeny, including adrenal and stress-induced secretion of cortisol and adrenocortico-trophic hormone (ACTH), and HPA axis regulation at the hypothalamic level. We also analysed the effect of the GRAla610Val substitution on different GC-modulated traits related to growth, body composition and immune responses. We examined the expression of GR target genes and GR signalling pathways in vivo in relevant tissues and ex vivo in DEX-treated peripheral blood mononuclear cells to gain insights into the molecular and physiological mechanisms of GR action.

2. Results

2.1. The GRAla610Val substitution does not negatively impact carrier viability

Two German Landrace sires heterozygous for the GRAla610Val substitution were each mated to five different heterozygous German Landrace dams, which gave birth to a total of 10 litters with 104 offspring (43 female and 61 male piglets in total). Genotype distribution in the offspring (AlaAla : AlaVal : ValVal = 22 : 51 : 27 per cent) was not significantly different from the expected 25 : 50 : 25 proportion (p = 0.480). Birth weight was not significantly influenced by the GRAla610Val Substitution or by GRAla610Val × sex (G × S) interaction (electronic supplementary material, table S1). These findings suggest that the GRAla610Val substitution did not negatively affect carrier viability.

2.2. Effect of the GRAla610Val substitution on basal and stress-induced cortisol and ACTH levels

We analysed basal plasma cortisol and ACTH levels one week post natum (pn) and 1 day before weaning (bw) and stress-induced levels 1 day after weaning (aw) and at a peri-puberal age in slaughter blood to examine whether the effect of the GRAla610Val substitution on HPA axis activity depended on age and/or animal state. All blood samplings were performed in the morning at the peak of HPA axis activity. The GRAla610Val genotype produced a significant effect on both parameters (p < 0.001 for cortisol and p = 0.015 for ACTH) in one-week-old piglets. Piglets carrying the Val variant exhibited significantly lower basal plasma cortisol and ACTH levels compared with homozygous wild-type AlaAla piglets (figures 1a and 2a; electronic supplementary material, table S1). Basal cortisol (p = 0.001), but not ACTH (p = 0.077), levels were significantly reduced by the GRAla610Val substitution one day before weaning (four weeks pn) (figures 1b and 2b; electronic supplementary material, table S1). Weaning pigs from the sow is one of the most stressful events in a pig’s life [18]. Accordingly, mean plasma cortisol and ACTH levels across all animals were significantly elevated 1 day after weaning (mean cortisol level increased from 18.7 ng ml⁻¹ bw to 34.0 ng ml⁻¹ aw, p < 0.001; mean ACTH level increased from 43.4 pg ml⁻¹ bw to 75.5 pg ml⁻¹ aw, p < 0.001). Although the relative change in cortisol levels between the two time points was similar in all three genotype groups, piglets carrying the Val variant exhibited significantly lower cortisol levels 1 day post-weaning compared with wild-type piglets (genotype p = 0.008; figure 1c; electronic supplementary material, table S1). Carriers of the Val variant also displayed lower ACTH levels compared with wild-type animals 1 day after weaning, but this difference did not reach statistical significance (genotype p = 0.111; figure 2c; electronic supplementary material, table S1). The Val variant was associated with significantly lower cortisol levels in slaughter blood (genotype p = 0.008), which is consistent with our previous study [17], but ACTH levels in carriers of the Val variant were non-significantly reduced compared with plasma ACTH levels of wild-type individuals (genotype p = 0.543; figures 1d and 2d; electronic supplementary material, table S1). Repeated measures analysis across all four sampling time points confirmed an overall trend of the GRAla610Val substitution to reduce plasma cortisol (genotype p < 0.001; electronic supplementary material, table S1) and ACTH levels (genotype p = 0.001; electronic supplementary material, table S1), which were approximately 40–50% lower in homozygous carriers of the Val variant compared with wild-type littermates.

2.3. The GRAla610Val substitution influences adrenal cortex, but not adrenal medulla, size

We found a markedly reduced weight of the adrenal glands in carriers of the Val variant (genotype p < 0.001; figure 3a; electronic supplementary material, table S1), which is consistent with the observed persistent reduction of cortisol production caused by the GRAla610Val substitution and our previous findings [17]. We performed histological analyses of both adrenal glands (only results for the left adrenal are presented here) to
**Figure 1.** Effect of the GR<sub>Ala610Val</sub> substitution on plasma cortisol levels. (a) Basal levels in one-week-old piglets; (b) basal levels one day before weaning; (c) stress-induced levels one day post-weaning; (d) stress-induced levels in peripubertal pigs. Data are presented as least-squares means ± s.e. *p < 0.05, **p < 0.01, ***p < 0.001.

**Figure 2.** Effect of the GR<sub>Ala610Val</sub> substitution on plasma ACTH levels. (a) Basal levels in 1-week-old piglets; (b) basal levels 1 day before weaning; (c) stress-induced levels 1 day post-weaning; (d) stress-induced levels in peripubertal pigs. Data are presented as least-squares means ± s.e. *p < 0.05.
investigate how the reduction in weight was reflected in adrenal structure. The results revealed a similar marked, highly significant reduction in size of the adrenal cortex associated with the Val variant (genotype $p < 0.001$; figure 3b; electronic supplementary material, table S1), but only a slight and insignificant reduction in the size of the adrenal medulla (genotype $p = 0.639$; figure 3c; electronic supplementary material, table S1). These changes resulted in a significantly reduced cortical/medullary ratio in carriers of the Val variant (genotype $p = 0.022$; electronic supplementary material, table S1). The results were similar for both adrenal glands (electronic supplementary material, table S1). Notably, the effect of the GRAla610Val substitution on AVP expression depended on carrier gender ($G \times S$ interaction, $p = 0.045$). Hypothalamic AVP expression was significantly downregulated by the GRAla610Val substitution in females (figure 4d), whereas castrated males (all male piglets were castrated 4 days postnatally) exhibited no differences in AVP expression between the different genotype groups (figure 4c; electronic supplementary material, table S1). We measured the mRNA expression of c-fos (FOS), which is a marker of neuronal activation following stress [19]. We found no significant effect of the GRAla610Val substitution (genotype $p = 0.823$) on FOS expression (figure 4b). This finding suggests that the observed differences in CRH and AVP expression between the different genotype groups of GRAla610Val were not caused by their differential reactivity to slaughter-associated stress.

2.4. Hypothalamic expression of corticotropin-releasing hormone and vasopressin is downregulated by the GRAla610Val substitution

We measured the mRNA expression of the two main ACTH secretagogues, corticotropin-releasing hormone (CRH) and vasopressin (AVP), in samples collected from peripubertal pigs using quantitative real time PCR (qPCR) to examine the impact of the GRAla610Val substitution on HPA axis regulation in the hypothalamus. The results demonstrated that CRH expression was significantly downregulated by the GRAla610Val substitution (genotype $p = 0.002$; figure 4b; electronic supplementary material, table S1). Notably, the effect of the GRAla610Val substitution on AVP expression depended on carrier gender ($G \times S$ interaction, $p = 0.045$). Hypothalamic AVP expression was significantly downregulated by the GRAla610Val substitution in females (figure 4d), whereas castrated males (all male piglets were castrated 4 days postnatally) exhibited no differences in AVP expression between the different genotype groups (figure 4c; electronic supplementary material, table S1). We measured the mRNA expression of c-fos (FOS), which is a marker of neuronal activation following stress [19]. We found no significant effect of the GRAla610Val substitution (genotype $p = 0.823$) on FOS expression (figure 4b). This finding suggests that the observed differences in CRH and AVP expression between the different genotype groups of GRAla610Val were not caused by their differential reactivity to slaughter-associated stress.

2.5. The GRAla610Val substitution does not significantly affect growth, body composition, blood chemistry or cell counts under baseline conditions

The GR is involved in the regulation of energy homeostasis and immune responses [1]. Therefore, we analysed effect of the GRAla610Val substitution on different related trait complexes (electronic supplementary material, table S1), including growth during the fattening period (average daily gain, average daily feed intake), body composition in

Figure 3. Effect of the GRAla610Val substitution on weight and structure of the adrenal gland (left). (a) Adrenal weight; (b) cross-sectional area of the adrenal cortex; (c) cross-sectional area of the adrenal medulla; (d) cortex/medulla ratio calculated using their cross-sectional areas. Data are presented as least-squares means $\pm$ s.e. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$. 

(a) adrenal weight

(b) adrenal cortex

(c) adrenal medulla

(d) cortex/medulla ratio

AlaAla (n = 17) AlaVal (n = 41) ValVal (n = 21)

AlaAla (n = 18) AlaVal (n = 41) ValVal (n = 20)

AlaAla (n = 18) AlaVal (n = 41) ValVal (n = 20)
peripubertal age (average backfat thickness, area of *M. longissimus dorsi*, estimated lean content, carcass length), blood chemistry (glucose, total cholesterol, triglyceride and blood urea nitrogen levels before weaning and in peripubertal age), and blood cell counts (leucocyte number, lymphocyte and neutrophil percentage and their ratio at all four blood sampling points). We found no significant effects of the GRAla610Val substitution on any of the analysed traits, except leucocyte number after weaning (genotype *p* = 0.002; electronic supplementary material, table S1).

2.6. Expression of SERPINA6, which encodes corticosteroid-binding globulin, is upregulated by the GRAla610Val substitution in liver

The apparent absence of detectable phenotypic consequences of the GRAla610Val substitution, except on HPA axis function, suggested that potential compensatory mechanisms balanced cortisol production and tissue responses to GC. Therefore, we analysed the expression of selected genes in hypothalamus (representing HPA axis tissues) and liver (representing peripheral tissues) sampled from peripubertal pigs using qPCR. These genes included GR targets (*GILZ, BDNF* and *PCK1*) in hypothalamus and liver, respectively), genes from the GC signalling pathway (*NR3C1, NR3C2, FKBPs* and *FKBP5*), and genes regulating the bioavailability of GC at the tissue level (*HSD11B1* and *HSD11B2*) and systemic level (*SERPINA6, SRD5A1* and *AKR1D1* in liver only).

We found no significant effects of the GRAla610Val substitution or the G × S interaction on the expression of selected genes in hypothalamus, including *NR3C1*, which encodes GR, and *NR3C2*, which encodes the mineralocorticoid receptor (electronic supplementary material, table S1).

We found significant effects of the GRAla610Val substitution on the hepatic expression of *FKBP4* (genotype *p* = 0.018) and *SERPINA6* (genotype *p* = 0.034; figure S), which encodes the corticosteroid-binding globulin (CBG), which is a major regulator of the systemic bioavailability and clearance of GC [20]. Both genes were upregulated in carriers of the Val variant (electronic supplementary material, table S1). We also found a significant effect of a G × S interaction on the expression of *HSD11B1* in liver (*p* = 0.020), but there was no clear direction of the effect (electronic supplementary material, table S1).

We further analysed the expression of genes from the CRH signalling pathway (*CRHR1, CRHR2* and *CRHBP*) in hypothalamus, but we found no significant effect of the GRAla610Val substitution (electronic supplementary material, table S1).

2.7. Glucocorticoid sensitivity of peripheral blood mononuclear cells is enhanced by the GRAla610Val substitution ex vivo

Circulating cortisol levels are reduced by the GRAla610Val substitution *in vivo*. Therefore, we examined the effect of the GRAla610Val substitution on tissue responses to equally strong GC stimuli. We analysed the transcriptional response of glucocorticoid-induced (*GILZ, FKBPs, DUSP1*) and -repressed (*IL2, TNFA, IFNG, IL1B*) genes [2,3] to different
DEX concentrations (0, 0.5, 5, 50 and 500 nM) in mitogen-stimulated (concanavalin A, ConA) peripheral blood mononuclear cells (PBMCs) ex vivo in cell culture. None of the genes exhibited significant differential expression associated with the GR\textsubscript{Ala610Val} Substitution in the absence of DEX (data not shown). Dose–response curves of the transcriptional response of GILZ and FKBP5 to DEX exhibited a notable leftward shift in homozygous ValVal individuals compared with PBMCs of wild-type AlaAla animals (figure 6a,b). However, the difference in estimated half-maximal effective concentrations (EC50) was not significant for any of the activated genes (electronic supplementary material, table S2). The estimated half-maximal inhibitory concentration (IC50) for repressed genes was significantly lower in PBMCs of homozygous ValVal animals compared with PBMCs of wild-type AlaAla animals for IL2 (p = 0.006), IFNG (p = 0.042) and IL1B (p = 0.004) (figures 7a,c,d; electronic supplementary material, table S2). The reduction in the IC50 of TNFA associated with GR\textsubscript{Ala610Val} approached statistical significance (p = 0.076, figure 7b; electronic supplementary material, S2). These results demonstrated that proinflammatory response of PBMCs of carriers of the GR\textsubscript{Ala610Val} substitution was more potently repressed by exogenous GC and confirmed the gain-of-function character of this mutation.

3. Discussion

Given the widespread expression of GR and its involvement in diverse biological processes, GR\textsubscript{Ala610Val} could potentially influence a broad spectrum of physiological functions. However, we found essentially no phenotypic manifestations of the substitution on growth, body composition, blood chemistries, including glucose, cholesterol and triglyceride levels, or blood cell counts, except for the approximately 40–50% reduction in HPA axis activity. Nevertheless, we found significantly lower leucocyte numbers 1 day after weaning in carriers of the substitution, which suggests that the effect of GR\textsubscript{Ala610Val} is revealed by exposure of the animals to certain stressors.

The apparent absence of phenotypic consequences of the GR\textsubscript{Ala610Val} substitution under baseline conditions is supported by findings in the mouse GR hypersensitivity model generated using a knock-in of the GR\textsubscript{M610L} substitution [16] (corresponding mutated Met residue is at position 609 in porcine GR). Mice carrying the gain-of-function allele displayed no obvious phenotypic abnormalities in serum electrolyte, glucose or lipid levels, bone mineral density, serum testosterone levels, or percentage body fat compared with wild-type littermates, but markedly reduced HPA axis activity was observed, which is similar to the natural pig model [16].

Figure 5. Effect of the GR\textsubscript{Ala610Val} substitution on expression of SERPINA6, which encodes corticosteroid-binding globulin, in liver of peripubertal pigs. SERPINA6 expression was measured using quantitative real time PCR. Data are presented as least-squares means ± s.e. *p < 0.05.

Figure 6. Transcriptional activation in ConA-stimulated PBMCs in response to DEX treatment ex vivo: (a) GILZ, (b) FKBP5; (c) DUSP1. Gene expression was measured using quantitative real time PCR. Data are presented as dose–response curves estimated based on fold-changes calculated within each individual relative to control treatment with ConA but without DEX. Individual points show means ± s.e. Estimated half-maximal effective concentrations (EC50) for AlaAla (n = 9) compared to ValVal (n = 10) carriers were: (a) 1.445 versus 0.957 nM (p = 0.561) for GILZ, (b) 3.857 versus 3.686 nM (p = 0.932) for FKBP5; (c) 2.156 versus 2.948 nM (p = 0.932) for DUSP1.
Specifically, adult mice expressing the gain-of-function mutation exhibited reduced basal and stress-induced cortisol and ACTH levels [16]. These results suggest that enhanced GR sensitivity due to structural mutations in the LBD induces a compensatory decrease in GC levels via an enhanced negative feedback regulation of the HPA axis to maintain an adequate GC response. This study found a significant reduction in basal cortisol and ACTH levels in carriers of the GRAla610Val substitution as early as one week post natum. This finding indicates that readjustment of the HPA axis activity due to GR hypersensitivity starts early in ontogeny. Examination of HPA axis regulation from early adolescence onward. Notably, the effect of the GRAla610Val substitution on basal and post-stress cortisol levels became subtle at weaning and puberty. Targeted disruption of GR in the pituitary (GR\textsuperscript{POMC\_Cre}) [22] and the paraventricular nucleus (PVN) of the hypothalamus (Sim1Cre-GR\textsubscript{E3delta}) [23] in mice revealed a key role of pituitary GR in the regulation of the HPA axis in early postnatal development, with PVN GR picking up in adolescence through adulthood [23]. Therefore, the effect of the GR\textsubscript{Ala610Val} substitution on ACTH level may be age-dependent. Notably, diverse models of GR deficiency (GR\textsuperscript{Noa\_Cre}; Sim1Cre-GR\textsubscript{E3delta}) [24,25] and a model of GR excess induced by GR overexpression (YGR) [26] exhibited a dissociation of GC and ACTH levels. A persistent reduction in cortisol production is likely in carriers of the GR\textsubscript{Ala610Val} substitution, which may be at least partially explained by the reduced capacity of the adrenal cortex to produce GC, which was indicated by its markedly reduced size. GR\textsubscript{Ala610Val} mice exhibited significantly lower corticosterone secretion even in response to ACTH stimulation [16], which provides supporting evidence for this conclusion. By contrast, the production of other corticosteroids was not affected, as evidenced by the lack of effect of the GR\textsubscript{Ala610Val} substitution on aldosterone levels, which implies a specific influence of the GR\textsubscript{Ala610Val} substitution on zona fasciculata cells. It remains to be elucidated whether the reduced size of the adrenal cortex was due to reduced ACTH levels earlier in ontogeny or whether it involves local GR effects in the adrenal gland [27] or its pre/perinatal development.

We found a significantly reduced expression of CRH and AVP in the hypothalamus of carriers of the gain-of-function variant at a peripubertal age, which is consistent with the hypothesis that PVN GR plays an important role in HPA axis regulation from early adolescence onward. Notably, the effect of the GR\textsubscript{Ala610Val} substitution on AVP expression only occurred in females. Sexual dimorphism in the regulation of AVP expression in rat PVN by GC was demonstrated, with a more pronounced downregulation of AVP in females [28]. However, we found no significant effect of the GR\textsubscript{Ala610Val} x sex interaction on ACTH or cortisol levels. Vasopressin alone is a relatively weak stimulus for ACTH secretion [29]; therefore,
the downregulation of CRH expression may be sufficient to reduce ACTH and cortisol levels in castrated males carrying the gain-of-function variant. CRH and AVP are not only central drivers of the HPA axis, but they also act as neuromodulators in the brain and affect among others higher mental functions, including emotion, cognition and behaviour [8]. We examined the expression of several genes from the CRH signalling pathway (CRHR1, CRHR2, CRHBP) in hypothalamus and found no compensatory changes associated with GR<sub>Ala610Val</sub>. Consequently, although the compensatory downregulation of GC levels probably alleviates some effects of GR hypersensitivity due to the GR<sub>Ala610Val</sub> substitution, this may still influence brain functions that are regulated by CRH and AVP independently of the HPA axis, for example behavioural responses to stress [30]. Notably, atypical depression shows similar features to HPA axis function in GR<sub>Ala610Val</sub> pigs. Atypical depression is characterized by centrally mediated hypocoactivation with low CRH levels, hypocortisolism and increased GC sensitivity, and it exhibits a markedly higher prevalence in women than men [31,32].

We also found no significant compensatory changes in the expression of several genes regulating GC action, including the GR gene NR3C1 itself, in the hypothalamus. By contrast, we found a significant upregulation of SERPINA6 in the liver of carriers of the gain-of-function allele. CBG, encoded by SERPINA6, is a major regulator of the systemic bioavailability of GC, and it sequesters approximately 80% of circulating GC in an inactive complex [20]. Therefore, upregulation of SERPINA6 should reduce free, biologically active GC and consequently dampen tissue GC responses, which may be an additional compensation mechanism for GR hypersensitivity caused by the GR<sub>Ala610Val</sub> substitution. It is likely that hepatic expression of SERPINA6 was readjusted earlier in ontogeny, similar to HPA axis activity. Increased GR activation in early ontogeny is able to induce concomitant readjustments of HPA axis activity and CBG secretion, which was evidenced by lower basal plasma cortisol and increased CBG concentrations in the offspring of sows stressed during gestation [33] or in neonatal pigs subjected to stressful handling [34]. Further research is needed to explain the molecular mechanisms and functional significance of SERPINA6 upregulation by the GR<sub>Ala610Val</sub> substitution.

To examine the impact of GR<sub>Ala610Val</sub> on gene expression in the absence of the systemic feedback regulation of GC levels, we analysed transcriptional response of several GR target genes in mitogen-stimulated PBMCs to DEX <em>ex vivo</em>. In this context, the effect of the substitution seems to be dependent on the overall responsiveness of the target gene expression to DEX and on the mode of its regulation by GR. GR regulates gene expression essentially either directly by binding to cognate response elements (GRE) in regulatory regions of target genes, or indirectly via interactions with other transcription factors and co-regulators [35,36]. The effect of GR<sub>Ala610Val</sub> was most pronounced for indirectly repressed genes (<em>e.g.</em> IL1B), while genes whose expression is directly activated by GR (<em>e.g.</em> GILZ) showed no significant differences. Until recently, it was generally believed that the therapeutic, anti-inflammatory action of GC is based on protein–protein interaction-dependent repression of inflammatory genes by GR monomers whereas undesirable side effects, for instance on metabolism, are based on direct gene activation by GR homodimers [5]. This model of functional separation of therapeutic and adverse effects initiated intensive efforts to develop GR ligands that could dissociate activation and repression by influencing oligomerization state of GR; however, so far these have met with little success [37,38]. There is mounting evidence that the original model of dissociation between activation and repression of gene expression by GR was oversimplified and that gene repression involves multiple mechanisms [37–39]. In view of the complexity of GR function and its intertwined physiological effects, the mechanism which favours effects of GR<sub>Ala610Val</sub> on repression over activation of gene expression in mitogen-stimulated PBMC and its relevance for phenotypic consequences of GR<sub>Ala610Val</sub> is not obvious. Different from this study, our previous <em>in vitro</em> analyses using a MMTV-driven reporter showed significantly enhanced transcriptional activity of the valine variant [17]. Hence, the effect of GR<sub>Ala610Val</sub> on transcriptional response appears to be context-dependent. Recent research suggests that contextual ability of GR to elicit specific transcriptional responses is conferred by the interaction between GR, co-regulators such as GRIP1, and the chromatin landscape [40,41]. There is evidence from the structural analysis of the LBD of the human GR that GR<sub>Ala610Val</sub> probably influences architecture of the GR-LBD and its interaction with ligands [42,43]. Changes in GR-LBD structure might expose different interacting surfaces and result in differential recruitment of co-regulators [36,44]. Thus, to better understand phenotypic consequences of GR<sub>Ala610Val</sub> future research should focus on its effect on GR regulatory networks and chromatin landscape in different cellular contexts and activation states.

Taken together, our results suggest that GR hypersensitivity induced by the GR<sub>Ala610Val</sub> substitution produces a compensatory reduction in bioactive GC levels, but it does not lead to notable alterations in GC-regulated processes and phenotypic traits under baseline conditions. We provide evidence for the first time that this compensation occurs early in ontogeny and involves CRH and AVP expression in hypothalamus and SERPINA6 expression in liver. Our results suggest that the effect of GR<sub>Ala610Val</sub> appears under stress exposure, particularly given the downregulation of CRH and AVP in hypothalamus. Carriers of the GR<sub>Ala610Val</sub> substitution are probably more sensitive to exogenous GC, as suggested by our analysis of the transcriptional response to GC in PBMCs. These features promote the use of pigs carrying the GR<sub>Ala610Val</sub> substitution as a valuable animal model to investigate the responses to GC-based drugs and explore mechanisms of HPA axis regulation, which may be relevant in the genetic basis of depression.

4. Material and methods

4.1. Animals and sample collection

The animals (purebred German Landrace pigs) used in this study were born and reared at the experimental pig farm of the Leibniz Institute for Farm Animal Biology (FBN) in Dummerstorf (Germany). Two sires heterozygous for the GR<sub>Ala610Val</sub> substitution were each bred using artificial insemination to five different heterozygous dams. All piglets (<em>n</em> = 104; 43 female and 61 male) were weighed at birth. Weak piglets weighing less than 800 g were excluded from subsequent experiments. This intervention did not alter genotype proportions (electronic supplementary material, table S1). Male piglets were castrated 4 days pn. Piglets were fed
ad libitum with standard diets (Trede & von Pein, Itzehoe, Germany) after weaning at four weeks pn. Pigs (n = 75; 32 females and 43 male castrates) were housed in pens equipped with an electronic feed dispenser (Insentec, B.V., Marknesse, The Netherlands) that recorded individual feed intake through ear tag transponders and weighed at 10, 15 and 19 weeks pn to measure growth and feed intake during the fattening period. Pigs were slaughtered in the experimental slaughter facility of the FBN, Dummerstorf after reaching a body weight of approximately 105 kg (approx. 22 weeks pn; peripubertal age). Animals were exsanguinated following electrocution and dissected (n = 80; 34 females and 46 male castrates). Phenotypic records, including body composition traits, were obtained according to German performance test directives.

Blood samples (5 ml) were obtained via rapid (less than or equal to 30 s) anterior vena cava puncture at the circadian peak of HPA axis activity (08.00) from one-week-old piglets, previously [17]. RNA extraction were frozen in liquid nitrogen and stored until use. PBMCs were prepared via centrifugation on a Histopaque density gradient (Sigma-Aldrich, Taufkirchen, Germany) and mounted on microscopic slides. Images of two representative sections of each gland were taken with a photo camera (VisiCam v. 3.0, VWR, Darmstadt, Germany) connected to a binocular. Area measurements of the complete adrenal cross-section and the medullary part were performed using VisiCam software (VisiCam IMAGE ANALYZER v. 6.23.1, VWR).

**4.5. Ex vivo dexamethasone treatment of peripheral blood mononuclear cells**

PBMCs were treated ex vivo with DEX according to Russcher et al. [47] with modifications. Cells were thawed and resuspended in RPMI 1640 medium with stable glutamine (Biochrom, Berlin, Germany) supplemented with 10% FBS, 100 U ml⁻¹ penicillin and 100 μg ml⁻¹ streptomycin (all PAA). PBMCs were incubated in a shaking water bath for 30 min at 37°C to remove endogenous cortisol. The medium was replaced, and 3 × 10⁶ cells per well were precultured overnight (5% CO₂, 37°C) in a 24-well plate at a density of 6 × 10⁶ cells ml⁻¹. The next day, PBMCs were incubated for 4 h with increasing DEX concentrations (0, 0.5, 5, 50 and 500 nM) together with 5 μg ml⁻¹ of the T-cell specific mitogen ConA (Sigma-Aldrich).

**4.6. Gene expression analysis**

Total RNA was isolated using TRI reagent (Sigma-Aldrich), DNasel-treated (Roche, Mannheim, Germany) and cleaned using the NucleoSpin RNA II Kit (Macherey-Nagel, Düren, Germany) for tissue samples or using the RNA clean & concentrator-5 Kit (Zymo, Freiburg, Germany) for cultured PBMCs. RNA quantity and purity were determined using a NanoDrop ND-1000 spectrophotometer (NanoDrop, Pehlab, Germany), and integrity was checked on 1% denaturing agarose gels.

First-strand cDNA was synthesized using SuperScript III MMLV reverse transcriptase (Invitrogen, Karlsruhe, Germany) in a reaction containing a mixture of 500 ng random hexamers (Promega, Mannheim, Germany), 500 ng of oligo (dT)11 VN primer and 1.5 μg RNA for tissue samples or 500 ng for cultured PBMCs, according to the manufacturer’s protocol.

Absolute quantification of the expression of genes of interest and reference genes (RP32L for tissue samples [48] and TSC22D2 for DEX-treated PBMCs [49]) was performed using qPCR in duplicate on a LightCycler 480 System using the LightCycler FastStart DNA Master SYBRplus Green I (Roche) kit. Information on primers and amplicons is summarized in the electronic supplementary material, table S2.

**4.7. Statistical analysis**

The effect of the GR_{Ala610Val} substitution on phenotypic traits and gene expression in tissues was analysed using linear
mixed models (MIXED procedure, SAS v. 9.3 software, SAS Inc., Cary, USA). The overall model included the fixed factors of GR_{A601Val} genotype and sex, and their interaction. The overall model further included the random effect of sire with banded main diagonal covariance structure, and the repeated effect of dam using the compound symmetry type of the block diagonal residual covariance matrix to account for genetic background. The model also included sampling order as a covariate for blood parameters and gene expression. The model included carcass or body weight as a covariate for body composition and organ morphometry, respectively. The total number of born piglets in a litter was fitted as a covariate for birth weight.

Least-squares means (LSM) of the genotype effect and their standard errors (SE) were calculated, and all pairwise differences of LSM were tested using the Tukey–Kramer procedure.

The transcriptional response of selected genes in ConA-stimulated PBMCs to DEX treatment was analysed by fitting dose-response curves using GRAPHPAD PRISM 5 (GraphPad Software, Inc., San Diego, CA).

Effects and differences were considered significant when \( p \leq 0.05 \).

**Ethics.** Animal care, handling and sample collection followed the guidelines of the German Law of Animal Protection. The Animal Care Committee of the Leibniz Institute for Farm Animal Biology and the State Mecklenburg-Western Pomerania (Landesamt für Landwirtschaft, Lebensmittelsicherheit und Fischerei, LALLF M-V/TSD/7221.3-2-1-010/12) approved the experimental protocol.

**Data accessibility.** Relevant data supporting this article have been uploaded as part of the electronic supplementary material.

**Authors’ contributions.** E.M. and K.W. conceived the study. A.G., A.J., E.M., S.P. and K.W. performed the experiments. E.M. analysed the data. A.T. provided statistical support. E.M. wrote the manuscript.

**Competing interests.** The authors have no conflict of interest to disclose.

**Funding.** This work was partially funded by the Phänomics network of competence (Federal Ministry of Education and Research) and matched funding from the FBN. The publication of this article was funded by the Open Access fund of the Leibniz Association.

Acknowledgements. The authors thank Janine Wetzel, Angela Garve, Hannelore Tychsen and Marlies Fuchs for excellent technical help.

**References**

1. Kadmiel M, Cidlowski JA. 2013 Glucocorticoid receptor signaling in health and disease. Trends Pharmacol. Sci. 34, 518 – 530. (doi:10.1016/j.tips.2013.07.003)

2. Donn R et al. 2007 Use of gene expression profiling to identify a novel glucocorticoid sensitivity determining gene, BMPRII. FASEB J. 21, 402 – 414. (doi:10.1096/fj.06-7236com)

3. Uhlenhaut NH, Barish GD, Yu RT, Downes M, Karanasii M, Liddle C, Schwalle P, Hübner N, Evans RM. 2013 Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes. Mol. Cell. 49, 158 – 171. (doi:10.1016/j.molcel.2012.10.013)

4. Wyns H, Meyer E, Watteyn A, Plessers E, De Baere S, De Backer P, Croubels S. 2013 Pharmacokinetics of denosumab: a human monoclonal antibody in patients with secondary hyperparathyroidism. J. Vasc. Interv. Radiol. 24, 313 – 322. (doi:10.1016/j.jvii.2013.06.015)

5. Schacke H, Schotteus A, Docke W-D, Strehlke P, Jaroch S, Schmes M, Rehwinkel H, Hennekes H, Asadullah K. 2004 Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl. Acad. Sci. USA 101, 227 – 232. (doi:10.1073/pnas.0300372101)

6. Maranville JC, Baxter SS, Witonsky DB, Chase MA, Di Pellegrino S. 2013 Genetic mapping with multiple levels of phenotypic information reveals determinants of lymphocyte glucocorticoid sensitivity. Am. J. Hum. Genet. 93, 735 – 743. (doi:10.1016/j.ajhg.2013.08.005)

7. de Kloet ER, Joels M, Holsboer F. 2005 Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 6, 463 – 475. (doi:10.1038/nrn1683)

8. Holsboer F, Ising M. 2010 Stress hormone regulation: biological role and translation into therapy. Annu. Rev. Psychol. 61, 81 – 109. (doi:10.1146/annurev.psych.093008.100321)

9. Reul JMHM, Collins A, Saliba RS, Mifsud KR, Carter SD, Gutierrez-Mecinas M, Qian X, Linhorst CAE. 2015 Glucocorticoids, epigenetic control and stress resilience. Neurobiol. Stress 1, 44 – 59. (doi:10.1016/j.jnstr.2014.10.001)

10. Wintermantel TM, Berger S, Greiner EF, Schutz G. 2004 Genetic dissection of corticosteroid receptor function in mice. Horm. Metab. Res. 36, 387 – 391. (doi:10.1055/s-2004-814567)

11. Beck IM, De BK, Haegeman G. 2011 Glucocorticoid receptor mutants: man-made tools for functional research. Trends Endocrinol. Metab. 22, 295 – 310. (doi:10.1016/j.tem.2011.03.009)

12. Nicolaiides NC, Charmandari E, Chrousos GP, Kino T. 2012 Recent advances in the molecular mechanisms determining tissue sensitivity to glucocorticoids: novel mutations, circadian rhythm and ligand-dependent repression of the human glucocorticoid receptor. BMC Endocr. Disord. 14, 71. (doi:10.1186/1472-6823-14-71)

13. Laryea G, Muglia L, Arnett M, Muglia LJ. 2015 Dissection of glucocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis by gene targeting in mice. Front. Neuroendocrinol. 36, 150 – 164. (doi:10.1016/j.yneuro.2014.09.002)

14. Krysiak R, Okopien B. 2012 Glucocorticoid hypersensitivity syndrome – a case report. West Indian Med. J. 61, 845 – 846. (doi:10.7727/wimj.2012.056).

15. Charmandari E, Kobayashi M, Shirome M, Laryea G. 2011 Primary generalized glucocorticoid resistance and hypersensitivity. J. Biol. Chem. 286, 6249 – 6259. (doi:10.1074/jbc.M807997200)

16. Murani E, Heyer R, Porsukski S, Fritschka S, Wimmers K. 2012 A substitution in the ligand binding domain of the porcine glucocorticoid receptor affects activity of the adrenal gland. PLoS ONE 7, e45518. (doi:10.1371/journal.pone.0045518)

17. Imaki T, Shibaoka T, Chikada N, Harada S, Naruse M, Demura H. 1996 Different expression of immediate-early genes in the rat paraventricular nucleus induced by stress: relation to corticotropin-releasing factor gene transcription. Endocr. J. 43, 629 – 638. (doi:10.1507/endocrj.63.629)

18. Campbell JH, Crenshaw JD, Polo J. 2013 The biological stress of early weaned piglets. J. Anim. Sci. Biotechnol. 4, 19. (doi:10.1186/2049-1891-4-19)

19. Imaki T, Shibasaki T, Chikada N, Harada S, Naruse M, Demura H. 1996 Different expression of immediate-early genes in the rat paraventricular nucleus induced by stress: relation to corticotropin-releasing factor gene transcription. Endocr. J. 43, 629 – 638. (doi:10.1507/endocrj.63.629)

20. Moisan MP, Minni AM, Dominguez G, Helbling JC, Faury A, Henkous N, Dorey R, Bézacchi D. 2014 Role of corticosteroid binding globulin in the fast actions of glucocorticoids on the brain. Steroids 81, 109 – 115. (doi:10.1016/j.steroids.2013.10.013)

21. Reichardt HM, Schutz G. 1996 Feedback control of glucocorticoid production is established during fetal development. Mol. Med. 2, 735 – 744.

22. Schmidt MV et al. 2009 Postnatal glucocorticoid excess due to pituitary glucocorticoid receptor deficiency: differential short- and long-term consequences. Endocrinology 150, 2709 – 2716. (doi:10.1210/en.2008-1211)

23. Laryea G, Muglia M, Muglia LJ. 2015 Ontogeny of hypothalamic glucocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in mice. Stress 18, 400 – 407. (doi:10.3109/10253890.2015.1046832)

24. Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orbán PC, Bock R, Klein R, Schütz G. 1999 Disruption of the glucocorticoid receptor gene in the...
nervous system results in reduced anxiety. Nat. Genet. 23, 99 – 103. (doi:10.1038/12703)

25. Laryea G, Schultz G, Muglia LJ. 2013 Disrupting hypothalamic glucocorticoid receptors causes HPA axis hyperactivity and excess adiposity. Mol. Endocrinol. 27, 1655 – 1665. (doi:10.1210/me.2013-1187)

26. Reichardt HM, Umland T, Bauer A, Kretz O, Schultz G. 2000 Mice with an increased glucocorticoid receptor gene dosage show enhanced resistance to stress and endotoxic shock. Mol. Cell. Biol. 20, 9009 – 9017. (doi:10.1128/MCB.20.23.9009-9017. 2000)

27. Gummow BM, Scheys JO, Cancelli VR, Hammer GD. 2006 Reciprocal regulation of a glucocorticoid receptor-stereoidogenic factor-1 transcription complex on the Daz-1 promoter by glucocorticoids and adrenocorticotropic hormone in the adrenal cortex. Mol. Endocrinol. 20, 2711 – 2723. (doi:10.1210/me.2005-0461)

28. Ferrini MG, Grillo CA, Pinoli G, de Kloet ER, De Nicola AF. 1997 Sex difference in glucocorticoid regulation of vasopressin mRNA in the paraventricular hypothalamic nucleus. Cell. Mol. Neurobiol. 17, 671 – 686. (doi:10.1023/A:1022538120627)

29. Abraham EJ, Minton JE. 1996 Effects of corticotropin-releasing hormone, lypressin vasopressin, oxytocin, and angiotensin II on adrenocorticotropin secretion from porcine anterior pituitary cells. Domest. Anim. Endocrinol. 13, 259 – 268. (doi:10.1016/0739-7240(96)00015-X)

30. Mennaghi F, Heinrichs SC, Pich EM, Weiss F, Koob GF. 1993 The role of limbic and hypothalamic corticotropin-releasing factor in behavioral responses to stress. Ann. N. Y. Acad. Sci. 697, 142 – 154. (doi:10.1111/j.1749-6632.1993.tb49929.x)

31. Gold PW, Chrousos GP. 2002 Organization of the neuroendocrine-behavior interactions. Annu. Rev. Pharmacol. Syst. Ther. 42, 481 – 508. (doi:10.1146/annurev.pharm.42.052201.135046)

32. Touma C. 2011 Stress and affective disorders: animal models elucidating the molecular basis of neuroendocrine-behavior interactions. Pharmacopsychiatry 44(Suppl 1), S15 – S26. (doi:10.1055/s-0031-2717702)

33. Otten W, Kanite Z, Tuchscherer M, Nurnberg G. 2001 Effects of prenatal restraint stress on hypothalamic-pituitary-adrenocortical and sympatho-adrenomedullary axis in neonatal pigs. Anim. Sci. 73, 279 – 287.

34. Weaver SA, Abemee FX, Meaney MJ, Schafere AL, Dixon WT. 2000 Neonatal handling permanently alters hypothalamic-pituitary-adrenal axis function, behavior, and body weight in boars. J. Endocrinol. 164, 349 – 359. (doi:10.1677/joe.0.1640349)

35. King EM, Chivers JE, Rider CF, Minnich A, Giembycz MA. 2003 Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation- and transrepression-dependent mechanisms. PLoS ONE 8, e53936. (doi:10.1371/journal.pone.0053936)

36. Saxa MA, Chinenov Y, Rogatsky I. 2016 Glucocorticoid signaling: an update from a genomic perspective. Annu. Rev. Physiol. 78, 155 – 180. (doi:10.1146/annurev-physiol-021115-105323)

37. De Boscher K, Beck IM, Ratman D, Berghe WV, Liber J. 2016 Activation of the glucocorticoid receptor in acute inflammation: the SEDIGRAM concept. Trends Pharmacol. Sci. 37, 4 – 16. (doi:10.1016/j.tips.2015.09.002)

38. Clark AB, Belvisi MG. 2012 Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. Pharmacol. Ther. 134, 54 – 67. (doi:10.1016/j.pharmthera.2011.12.004)

39. Hübner S, Dejager L, Libert C, Tuckermann JP. 2015 The glucocorticoid receptor in inflammatory processes: transrepression is not enough. Arch. Biochem. Biophys. 561, 1 – 12. (doi:10.1016/j.abb.2015.08.024)

40. Chinenov Y, Gupte R, Rogatsky I. 2013 Nuclear receptors in inflammation control: repression by GR and beyond. Mol. Cell. Endocrinol. 380, 55 – 64. (doi:10.1016/j.mce.2013.04.006)

41. Greulich F, Hemmer MC, Rolls DA, Rogatsky I, Uhlenhaut NH. In press. There goes the glucocorticoid receptor gene (NR3C1).

42. Setz T et al. 2010 Enhancing the stability and solubility of the glucocorticoid receptor ligand-binding domain by high-throughput library screening. J. Mol. Biol. 403, 562 – 577. (doi:10.1016/j.jmb.2010.08.048)

43. Carson MW et al. 2014 Glucocorticoid receptor modulators identified by crystallography lead to a novel rationale for receptor selectivity, function, and implications for structure-based design. J. Med. Chem. 57, 849 – 860. (doi:10.1021/jm401616g)

44. Ronacher K, Hadley K, Awenet C, Stubsrud E, Simons SS, Louw A, Haggop JD. 2009 Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction. Mol. Cell. Endocrinol. 299, 219 – 231. (doi:10.1016/j.mce.2008.10.008)

45. Felix B et al. 1999 Stereotoxic atlas of the pig brain. Brain Res. Bull. 49, 1 – 137. (doi:10.1016/S0361-9230(99)00012-X)

46. Kanite Z, Hameister T, Tuchscherer M, Tuchscherer A, Puppe B. 2014 Social support attenuates the adverse consequences of social deprivation stress in domestic piglets. Horm. Behav. 65, 203 – 210. (doi:10.1016/j.yhbeh.2014.01.007)

47. Russcher H, Smit P, van den Akker ELT, van Rossum EFC, Brinkmann AD, de Jong FH, Lamberts SWJ, Koper J. 2005 Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression. J. Clin. Endocrinol. Metab. 90, 5804 – 5810. (doi:10.1210/jc.2005-0646)

48. Reyer H, Ponsuksci, Wimmers K, Murani E. 2013 Transcript variants of the porcine glucocorticoid receptor gene (NR3C1). Gen. Comp. Endocrinol. 189, 127 – 133. (doi:10.1016/j.ygcen.2013.04.038)

49. Oster M, Schell M, Murani E, Ponsuksci, S, Zebunke M, Puppe B, Wimmers K. 2015 The fight-or-flight response is associated with PBMC expression profiles related to immune defense and recovery in swine. PLoS ONE 10, e0120153. (doi:10.1371/journal.pone.0120153)